Pulse Biosciences, Inc. (PLSE) · Nov 6, 2026 · Other events
Above the bar — 86% reached ≥50% reduction; median reduction 72%
Pulse Biosciences’ thyroid trial delivers strong six-month interim data, but the result strengthens a secondary program rather than rewriting its AF-led story.
Pulse Biosciences is primarily building its nsPFA platform around atrial-fibrillation catheters, while Vybrance remains in a controlled commercial launch and the thyroid program is a smaller supporting application. The company had already completed enrollment of 100 PRECISE-BTN patients in September and previewed interim data, so the direction was anticipated; the efficacy and safety magnitude is the new information.
The study cleared its stated efficacy bar decisively. The primary endpoint required at least 50% nodule-volume reduction at six months, and 86% of evaluated patients reached it, with a 72% median reduction. That is a meaningful validation of the early feasibility work in a prospective, multicenter study rather than just a favorable early case series. 〔0〕 〔1〕
| Measure | Six months | Benchmark |
|---|---|---|
| Patients reaching ≥50% reduction (Study results) | 86% | 50% endpoint |
| Median nodule-volume reduction (Study results) | 72% | 50% endpoint |
| Quality-of-life improvement (Quality of life and symptomatic relief) | 78% | Baseline |
| Neck-pressure/fullness resolution (Quality of life and symptomatic relief) | 82% | Baseline |
The clinical profile strengthens the product’s practical case. The release reports no serious adverse events, significant symptom and quality-of-life improvements, and preserved thyroid function in hyperfunctioning-nodule patients, although the interim update does not provide a full adverse-event table or comparative control arm. 〔2〕 〔3〕
The impact is positive but contained at the company level. These data advance the thyroid/Vybrance application and support the claim that early feasibility results can be reproduced across three U.S. centers, but Pulse is allocating its primary effort toward atrial-fibrillation devices. The result therefore improves confidence in the broader platform without yet changing the central regulatory, commercialization, or revenue story.
Bottom line: This is a solid clinical validation for the thyroid application and better than the study’s minimum success bar. It matters, but mainly as incremental platform support while the company’s larger value-creating program remains atrial fibrillation.
Full six-month and 12-month PRECISE-BTN follow-up data
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!